The value of biomarkers in rescuing oncology R&D
Amsterdam – this weekend it’s time to showcase some important updates in hematology from the European Hematology Association (EHA).
It’s really hard not to like continental Europe when you see scenes like this from a major conference:
A flavor of Amsterdam #EHA24 pic.twitter.com/Am4B3jutwL
— Mohamad Mohty (@Mohty_EBMT) June 13, 2019
T cell lymphomas is not a topic we cover very often but it looks like it will receive attention here three times in a month with news from Corvus at ASCO and now an update on the intriguing story on CXCL12-positive AML and PTCL from Kura Oncology.
We’ve been following the latter story for a while now and after the previous looks at the rationale behind the translational data, it’s now time to explore what happens in clinical practice from their ongoing phase 2 clinical trial…
To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers